References
- Braunwald E, Lambrew CT, Rockoff SD, Ross J
Jr , Morrow AG. Idiopathic Hypertrophic Subaortic Stenosis. I. A Description of the Disease Based Upon an Analysis of 64 Patients. Circulation. 1964 Nov;30(SUPPL 4):3-119. doi: 10.1161/01.cir.29.5s4.iv-3 - Braunwald E. Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11;393(10):1004-1015. doi: 10.1056/NEJMra2413445
- Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194
- Playford D, Strange GA, Atherton JJ, Harris S, Chan YK, Stewart S. Clinical to Population Prevalence of Hypertrophic Cardiomyopathy Phenotype: Insights From the National Echo Database Australia. Heart Lung Circ. 2024 Feb;33(2):212-221. doi: 10.1016/j.hlc.2023.10.021
- Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol. 1983 Sep;2(3):437-444. doi: 10.1016/s0735-1097(83)80269-1
- de Marvao A, McGurk KA, Zheng SL, et al. Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021 Sep 14;78(11):1097-1110. doi: 10.1016/j.jacc.2021.07.017
- Lopes LR, Aung N, van Duijvenboden S, Munroe PB, Elliott PM, Petersen SE. Prevalence of Hypertrophic Cardiomyopathy in the UK Biobank Population. JAMA Cardiol. 2021 Jul 1;6(7):852-854. doi: 10.1001/jamacardio.2021.0689
- Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995 Aug 15;92(4):785-789. doi: 10.1161/01.cir.92.4.785
- Bai Y, Zheng JP, Lu F, Z, et al. Prevalence, incidence and mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9 million in China. Sci Rep. 2022 Nov 5;12(1):18799. doi: 10.1038/s41598-022-20042-9
- Neubauer S, Kolm P, Ho CY, et al. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol. 2019 Nov 12;74(19):2333-2345. doi: 10.1016/j.jacc.2019.08.1057
- Zhao H, Tan Z, Liu M, et al. Is There a Sex Difference in the Prognosis of Hypertrophic Cardiomyopathy? A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2023 Jun 6;12(11):
e026270 . doi: 10.1161/JAHA.122.026270 - Evans W. Familial cardiomegaly. Br Heart J. 1949 Jan;11(1):68-82. doi: 10.1136/hrt.11.1.68
- Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958 Jan;20(1):1-8. doi: 10.1136/hrt.20.1.1
- Pare JA, Fraser RG, Pirozynski WJ, Shanks JA, Stubington D. Hereditary cardiovascular dysplasia.A form of familial cardiomyopathy. Am J Med. 1961 Jul;31:37-62. doi: 10.1016/0002-9343(61)90222-4
- Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990 Sep 7;62(5):999-1006. doi: 10.1016/0092-8674(90)90274-i
- Marian AJ. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Circ Res. 2021 May 14;128(10):1533-1553. doi: 10.1161/CIRCRESAHA.121.318346
- Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995 Apr 20;332(16):1058-1064. doi: 10.1056/NEJM199504203321603
- Kimura A, Harada H, Park JE, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. 1997 Aug;16(4):379-382. doi: 10.1038/ng0897-379
- Genomes Project C; Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015 Oct 1;526(7571):68-74. doi: 10.1038/nature15393
- Lander ES, Linton LM, Birren B, et al.; International Human Genome Sequencing C. Initial sequencing and analysis of the human genome. Nature. 2001 Feb 16;409(6822):860-921. doi: 10.1038/35057062
- Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004 Nov 2;44(9):1903-1910. doi: 10.1016/j.jacc.2004.07.045
- Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol. 2010 Apr 6;55(14):1444-1453. doi: 10.1016/j.jacc.2009.11.062
- Li L, Bainbridge MN, Tan Y, Willerson JT, Marian AJ. A Potential Oligogenic Etiology of Hypertrophic Cardiomyopathy: A Classic Single-Gene Disorder. Circ Res. 2017 Mar 31;120(7):1084-1090. doi: 10.1161/CIRCRESAHA.116.310559
- Pourebrahim K, Marian JG, Tan Y, Chang JT, Marian AJ. A combinatorial oligogenic basis for the phenotypic plasticity between late-onset dilated and arrhythmogenic cardiomyopathy in a single family. J Cardiovasc Aging. 2021:1:12. doi: 10.20517/jca.2021.15
- Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017 Feb;19(2):192-203. doi: 10.1038/gim.2016.90
- Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015 Nov;17(11):880-888. doi: 10.1038/gim.2014.205
- Ingles J, Burns C, Bagnall RD, et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circ Cardiovasc Genet. 2017 Apr;10(2):
e001620 . doi: 10.1161/CIRCGENETICS.116.001620 - Daw EW, Chen SN, Czernuszewicz G, et al. Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet. 2007 Oct 15;16(20):2463-2471. doi: 10.1093/hmg/ddm202
- Carrier L, Mearini G, Stathopoulou K, Cuello F. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene. 2015 Dec 1;573(2):188-197. doi: 10.1016/j.gene.2015.09.008
- Greenman AC, de Lange W, Ralphe JC. Post-translational modifications of cardiac myosin-binding protein-C: Mechanisms behind fine-tuning the sarcomere. J Gen Physiol. 2026 May 4;158(3):
e202513889 . doi: 10.1085/jgp.202513889 - Main A, Fuller W, Baillie GS. Post-translational regulation of cardiac myosin binding protein-C: A graphical review. Cell Signal. 2020 Dec;76:109788. doi: 10.1016/j.cellsig.2020.109788
- Harper AR, Bowman M, Hayesmoore JBG, et al. Reevaluation of the South Asian MYBPC3(Delta25bp) Intronic Deletion in Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2020 Jun;13(3):
e002783 . doi: 10.1161/CIRCGEN.119.002783 - Adalsteinsdottir B, Teekakirikul P, Maron BJ, et al. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation. Circulation. 2014 Sep 30;130(14):1158-1167. doi: 10.1161/CIRCULATIONAHA.114.011207
- Alders M, Jongbloed R, Deelen W, et al. The 2373 insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003 Oct;24(20):1848-1853. doi: 10.1016/s0195-668x(03)00466-4
- Vignier N, Schlossarek S, Fraysse B, et al. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res. 2009 Jul 31;105(3):239-248. doi: 10.1161/CIRCRESAHA.109.201251
- Seeger T, Shrestha R, Lam CK, et al. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay. Circulation. 2019 Feb 5;139(6):799-811. doi: 10.1161/CIRCULATIONAHA.118.034624
- van Dijk SJ, Dooijes D, dos Remedios C, et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009 Mar 24;119(11):1473-1483. doi: 10.1161/CIRCULATIONAHA.108.83867
- Marston S, Copeland O, Jacques A, et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res. 2009 Jul 31;105(3):219-222. doi: 10.1161/CIRCRESAHA.109.202440
- Helms AS, Thompson AD, Glazier AA, et al. Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2020 Oct;13(5):396-405. doi: 10.1161/CIRCGEN.120.002929
- Stelzer JE, Patel JR, Moss RL. Protein kinase A-mediated acceleration of the stretch activation response in murine skinned myocardium is eliminated by ablation of cMyBP-C. Circ Res. 2006 Oct 13;99(8):884-890. doi: 10.1161/01.RES.0000245191.34690.66
- McNamara JW, Singh RR, Sadayappan S. Cardiac myosin binding protein-C phosphorylation regulates the super-relaxed state of myosin. Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11731-11736. doi: 10.1073/pnas.1821660116
- Kuster DW, Sequeira V, Najafi A, et al. GSK3beta phosphorylates newly identified site in the proline-alanine-rich region of cardiac myosin-binding protein C and alters cross-bridge cycling kinetics in human: short communication. Circ Res. 2013 Feb 15;112(4):633-639. doi: 10.1161/CIRCRESAHA.112.275602
- Brunello E, Fusi L. Regulating Striated Muscle Contraction: Through Thick and Thin. Annu Rev Physiol. 2024 Feb 12;86:255-275. doi: 10.1146/annurev-physiol-042222-022728
- McNamara JW, Li A, Lal S, et al. MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy. PLoS One. 2017 Jun 28;12(6):
e0180064 . doi: 10.1371/journal.pone.0180064 - Toepfer CN, Wakimoto H, Garfinkel AC, et al. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci Transl Med. 2019 Jan 23;11(476):
eaat1199 . doi: 10.1126/scitranslmed.aat1199 - Marian AJ, Yu QT, Mares A
Jr , Hill R, Roberts R, Perryman MB. Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. J Clin Invest. 1992 Dec;90(6):2156-2165. doi: 10.1172/JCI116101 - Armel TZ, Leinwand LA. A mutation in the beta-myosin rod associated with hypertrophic cardiomyopathy has an unexpected molecular phenotype. Biochem Biophys Res Commun. 2010 Jan 1;391(1):352-356. doi: 10.1016/j.bbrc.2009.11.062
- Tajsharghi H, Thornell LE, Lindberg C, Lindvall B, Henriksson KG, Oldfors A. Myosin storage myopathy associated with a heterozygous missense mutation in MYH7. Ann Neurol. 2003 Oct;54(4):494-500. doi: 10.1002/ana.10693
- Meredith C, Herrmann R, Parry C, et al. Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause laing early-onset distal myopathy (MPD1). Am J Hum Genet. 2004 Oct;75(4):703-708. doi: 10.1086/424760
- Jaaskelainen P, Helio T, Aalto-Setala K, et al. A new common mutation in the cardiac beta-myosin heavy chain gene in Finnish patients with hypertrophic cardiomyopathy. Ann Med. 2014 Sep;46(6):424-429. doi: 10.3109/07853890.2014.912834
- Stewart MA, Franks-Skiba K, Chen S, Cooke R. Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):430-435. doi: 10.1073/pnas.0909468107
- Hooijman P, Stewart MA, Cooke R. A new state of cardiac myosin with very slow ATP turnover: a potential cardioprotective mechanism in the heart. Biophys J. 2011 Apr 20;100(8):1969-1976. doi: 10.1016/j.bpj.2011.02.061
- Nag S, Trivedi DV. To lie or not to lie: Super-relaxing with myosins. Elife. 2021 Feb 10;10:
e63703 . doi: 10.7554/eLife.63703 - Toepfer CN, Garfinkel AC, Venturini G, et al. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. Circulation. 2020 Mar 10;141(10):828-842. doi: 10.1161/CIRCULATIONAHA.119.042339
- Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A. 2018 Aug 28;115(35):E8143-E8152. doi: 10.1073/pnas.1809540115
- Yuan CC, Kazmierczak K, Liang J, Ma W, Irving TC, Szczesna-Cordary D. Molecular basis of force-pCa relation in MYL2 cardiomyopathy mice: Role of the super-relaxed state of myosin. Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):
e2110328119 . doi: 10.1073/pnas.2110328119 - Pilagov M, Heling L, Walklate J, Geeves MA, Kad NM. Single-molecule imaging reveals how mavacamten and PKA modulate ATP turnover in skeletal muscle myofibrils. J Gen Physiol. 2023 Jan 2;155(1):
e202213087 . doi: 10.1085/jgp.202213087 - Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003 May 21;41(10):1776-1782. doi: 10.1016/s0735-1097(02)03009-7
- Witjas-Paalberends ER, Guclu A, Germans T, et al. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res. 2014 Jul 15;103(2):248-257. doi: 10.1093/cvr/cvu127
- Ranjbarvaziri S, Kooiker KB, Ellenberger M, et al. Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy. Circulation. 2021 Nov 23;144(21):1714-1731. doi: 10.1161/CIRCULATIONAHA.121.053575
- Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016 Feb 5;351(6273):617-621. doi: 10.1126/science.aad3456
- Chuang C, Collibee S, Ashcraft L, et al. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021 Oct 14;64(19):14142-14152. doi: 10.1021/acs.jmedchem.1c01290
- Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X
- Maron MS, Masri A, Nassif ME, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024 May 30;390(20):1849-1861. doi: 10.1056/NEJMoa2401424
- Desai MY, Owens AT, Abraham T, et al. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11;393(10):961-972. doi: 10.1056/NEJMoa2505927
- Heissler SM and Sellers JR. Various Themes of Myosin Regulation. J Mol Biol. 2016 May 8;428(9 Pt B):1927-1946. doi: 10.1016/j.jmb.2016.01.022
- Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun. 1999 Aug 27;262(2):411-417. doi: 10.1006/bbrc.1999.1221
- Landstrom AP, Parvatiyar MS, Pinto JR, et al. Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. J Mol Cell Cardiol. 2008 Aug;45:281-288. doi: 10.1016/j.yjmcc.2008.05.003
- Marston S, Zamora JE. Troponin structure and function: a view of recent progress. J Muscle Res Cell Motil. 2020 Mar;41(1):71-89. doi: 10.1007/s10974-019-09513-1
- Mogensen J, Klausen IC, Pedersen AK, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest. 1999 May 15;103(10):R39-R43. doi: 10.1172/JCI6460
- Olson TM, Doan TP, Kishimoto NY, Whitby FG, Ackerman MJ, Fananapazir L. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2000 Sep;32(9):1687-1694. doi: 10.1006/jmcc.2000.1204
- Sorimachi H, Freiburg A, Kolmerer B, et al. Tissue-specific expression and alpha-actinin binding properties of the Z-disc titin: implications for the nature of vertebrate Z-discs. J Mol Biol. 1997 Aug 1;270(5):688-695. doi: 10.1006/jmbi.1997.1145
- Ranta-Aho J, Olive M, Vandroux M, et al. Mutation update for the ACTN2 gene. Hum Mutat. 2022 Dec;43(12):1745-1756. doi: 10.1002/humu.24470
- Chiu C, Bagnall RD, Ingles J, et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. J Am Coll Cardiol. 2010 Mar 16;55(11):1127-1135. doi: 10.1016/j.jacc.2009.11.016
- Geier C, Gehmlich K, Ehler E, et al. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Hum Mol Genet. 2008 Sep 15;17(18):2753-2765. doi: 10.1093/hmg/ddn160
- Wei Xk, Zhang H. Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression. Cancer Biol Med. 2020 May 15;17(2):270-281. doi: 10.20892/j.issn.2095-3941.2019.0420
- Lim DS, Roberts R, Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J Am Coll Cardiol. 2001 Oct;38(4):1175-1180. doi: 10.1016/s0735-1097(01)01509-1
- Caputo M, Schoser B. The FHL1 myopathy spectrum revisited: a literature review and report of two new patients. Acta Myol. 2024 Dec;43(4):123-129. doi: 10.36185/2532-1900-604
- Gueneau L, Bertrand AT, Jais JP, et al. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet. 2009 Sep;85(3):338-353. doi: 10.1016/j.ajhg.2009.07.015
- Friedrich FW, Wilding BR, Reischmann S, et al. Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. Hum Mol Genet. 2012 Jul 15;21(14):3237-3254. doi: 10.1093/hmg/dds157
- Osio A, Tan L, Chen SN, et al. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res. 2007 Mar 30;100(6):766-768. doi: 10.1161/01.RES.0000263008.66799.aa
- Takada F, Vander Woude DL, Tong HQ, et al. Myozenin: an alpha-actinin- and gamma-filamin-binding protein of skeletal muscle Z lines. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1595-1600. doi: 10.1073/pnas.98.4.1595
- Frank D, Kuhn C, van Eickels M, et al. Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy. Circulation. 2007 Nov 27;116(22):2587-2596. doi: 10.1161/CIRCULATIONAHA.107.711317
- Ruggiero A, Chen SN, Lombardi R, Rodriguez G, Marian AJ. Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity. Cardiovasc Res. 2013 Jan 1;97(1):44-54. doi: 10.1093/cvr/cvs294
- Valencia DA, Koeberlein AN, Nakano H, et al. Human formin FHOD3-mediated actin elongation is required for sarcomere integrity in cardiomyocytes. Elife. 2025 Jul 15;13:RP104048. doi: 10.7554/eLife.104048
- Wooten EC, Hebl VB, Wolf MJ, et al. Formin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2013 Feb;6(1):10-18. doi: 10.1161/CIRCGENETICS.112.965277
- Hayashi T, Tanimoto K, Hirayama-Yamada K, et al. Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy. J Hum Genet. 2018 Sep;63(9):989-996. doi: 10.1038/s10038-018-0479-y
- Arimura T, Takeya R, Ishikawa T, et al. Dilated cardiomyopathy-associated FHOD3 variant impairs the ability to induce activation of transcription factor serum response factor. Circ J. 2013;77(12):2990-2996. doi: 10.1253/circj.cj-13-0255
- Harper AR, Goel A, Grace C, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet. 2021 Feb;53(2):135-142. doi: 10.1038/s41588-020-00764-0
- Tadros R, Zheng SL, Grace C, et al. Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy. Nat Genet. 2025 Feb;57(2):530-538. doi: 10.1038/s41588-020-00764-0
- Verdonschot JAJ, Vanhoutte EK, Claes GRF, et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat. 2020 Jun;41(6):1091-1111. doi: 10.1002/humu.24004
- Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol. 2016 Dec 6;68(22):2440-2451. doi: 10.1016/j.jacc.2016.09.927
- Zhang M, Liu J, Cheng A, Deyoung SM, Saltiel AR. Identification of CAP as a costameric protein that interacts with filamin C. Mol Biol Cell. 2007 Dec;18(12):4731-4740. doi: 10.1091/mbc.e07-06-0628
- Kamm KE, Stull JT. Signaling to myosin regulatory light chain in sarcomeres. J Biol Chem. 2011 Mar 25;286(12):9941-9947. doi: 10.1074/jbc.R110.198697
- Davis JS, Hassanzadeh S, Winitsky S, et al. The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation. Cell. 2001 Nov 30;107(5):631-641. doi: 10.1016/s0092-8674(01)00586-4
- Richard P, Isnard R, Carrier L, et al. Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J Med Genet. 1999 Jul;36(7):542-545. PMID: 10424815.
- Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005 Oct;42(10):
e59 . doi: 10.1136/jmg.2005.033886 - Marian AJ, Belmont J. Strategic approaches to unraveling genetic causes of cardiovascular diseases. Circ Res. 2011 May 13;108(10):1252-1269. doi: 10.1161/CIRCRESAHA.110.236067
- Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018 Oct 2;138(14):1387-1398. doi: 10.1161/CIRCULATIONAHA.117.033200
- de Feria AE, Kott AE, Becker JR. Sarcomere mutation negative hypertrophic cardiomyopathy is associated with ageing and obesity. Open Heart. 2021 Feb;8(1):
e001560 ). doi: 10.1136/openhrt-2020-001560 - Huang Z, Lin K, Huang J, et al. Characteristics and outcomes associated with sarcomere mutations in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol. 2024 Aug 15;409:132213. doi: 10.1016/j.ijcard.2024.132213
- Genomes Project C; Abecasis GR, Altshuler D, Auton A, et al. A map of human genome variation from population-scale sequencing. Nature. 2010 Oct 28;467(7319):1061-1073. doi: 10.1038/nature09534
- Halldorsson BV, Eggertsson HP, Moore KHS, et al. The sequences of 150,119 genomes in the UK Biobank. Nature. 2022 Jul;607(7920):732-740. doi: 10.1038/s41586-022-04965-x
- International HapMap C. A haplotype map of the human genome. Nature. 2005 Oct 27;437(7063):1299-1320. doi: 10.1038/nature04226
- Pope RK, Pestonjamasp KN, Smith KP, et al. Cloning, characterization, and chromosomal localization of human superillin (SVIL). Genomics. 1998 Sep 15;52(3):342-351. doi: 10.1006/geno.1998.5466
- Smith TC, Fridy PC, Li Y, et al. Supervillin binding to myosin II and synergism with anillin are required for cytokinesis. Mol Biol Cell. 2013 Dec;24(23):3603-3619. doi: 10.1091/mbc.E12-10-0714
- Hagege A, Puscas T, El Hachmi M, et al. The French hypertrophic cardiomyopathy gene register: A systematic large gene screening for hypertrophic cardiomyopathy. Int J Cardiol. 2024 Dec 15;417:132542. doi: 10.1016/j.ijcard.2024.132542
- Silajdzija E, Vissing CR, Christensen EB, et al. Family Screening in Hypertrophic Cardiomyopathy: Identification of Relatives With Low Yield From Systematic Follow-Up. J Am Coll Cardiol. 2024 Nov 5;84(19):1854-1865. doi: 10.1016/j.jacc.2024.08.011
- Antheia K, Eva F, Jan-Erik K, Henrik G, Rada E, Cecilia G. Genetic determinants of the phenotype in a Swedish cohort of patients with hypertrophic cardiomyopathy. Sci Rep. 2025 Nov 10;15(1):39357. doi: 10.1038/s41598-025-27238-9
- Consortium UKBW-GS. Whole-genome sequencing of 490,640 UK Biobank participants. Nature. 2025 Sep;645(8081):692-701. doi: 10.1038/s41586-025-09272-9
- Marian AJ. Clinical Interpretation and Management of Genetic Variants. JACC Basic Transl Sci. 2020 Oct 16;5(10):1029-1042. doi: 10.1016/j.jacbts.2020.05.013
- Marian AJ. Gene-based renaming of human diseases. Curr Opin Cardiol. 2024 May 1;39(3):135-137. doi: 10.1097/HCO.0000000000001123
- Chai AC, Cui M, Chemello F, et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat Med. 2023 Feb;29(2):401-411. doi: 10.1038/s41591-022-02176-5
- Reichart D, Newby GA, Wakimoto H, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023 Feb;29(2):412-421. doi: 10.1038/s41591-022-02190-7
- Cail RC, Barua B, Baez-Cruz FA, Winkelmann DA, Goldman YE, Ostap EM. A myosin hypertrophic cardiomyopathy mutation disrupts the super-relaxed state and boosts contractility by enhanced actin attachment. Proc Natl Acad Sci U S A. 2025 Jul 22:2025.06.02.657466. doi: 10.1101/2025.06.02.657466
- Previs MJ, O’Leary TS, Morley MP, et al. Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy. Circ Heart Fail. 2022 Jun;15(6):
e009521 . doi: 10.1161/CIRCHEARTFAILURE.121.009521
DOI: https://doi.org/10.14797/mdcvj.1900 | Journal eISSN: 1947-6108
Language: English
Page range: 51 - 67
Submitted on: Jun 20, 2026
Accepted on: Jul 27, 2026
Published on: Sep 15, 2026
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2026 A. J. Marian, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.